Cullinan Oncology LLC

NASDAQ CGEM

Data sourced from

and

Download Data

Cullinan Oncology LLC Asset Turnover Ratio 1 year YoY Change (%) for the quarter ending December 31, 2022: 100.00%

Cullinan Oncology LLC Asset Turnover Ratio 1 year YoY Change (%) is 100.00% for the quarter ending December 31, 2022. The asset turnover ratio measures a company's efficiency in utilizing its assets to generate revenue. It is calculated by dividing the company's revenue by the average of its total assets and total non-current assets. This ratio indicates how effectively a company generates sales from its asset base. A higher ratio implies better asset utilization and revenue generation, while a lower ratio may suggest underutilization of assets or inefficient operations. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Cullinan Oncology LLC Asset Turnover Ratio for the quarter ending March 31, 2023 was 0.00, a 0.00% change year over year.
Cullinan Oncology LLC Asset Turnover Ratio for the quarter ending March 31, 2022 was 0.00, a -100.00% change year over year.
Cullinan Oncology LLC Asset Turnover Ratio for the quarter ending March 31, 2021 was 0.08.

NASDAQ: CGEM

Cullinan Oncology LLC

CEO	Mr. Nadim Ahmed
IPO Date	Jan. 8, 2021
Location	United States
Headquarters	One Main Street, Cambridge, MA, United States, 02142
Employees	85
Sector	Healthcare
Industry	Biotechnology

Description

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Key trends